ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer

Oppenheimer analyst Jeff Jones raised the firm’s price target on ArriVent Biopharma (AVBP) to $50 from $44 and keeps an Outperform rating on the shares. The firm notes that Thursday afternoon, ArriVent provided a full-year business update, including revised guidance on the timing of top-line pivotal Phase 3 results from the FURVENT trial, evaluating firmonertinib in NSCLC with firt line EGFR Ex20ins mutations. The company revised expectations for timing of data from “early 2026” to “mid-2026.” In an event driven study, this suggests patients on therapy could be seeing a greater benefit vs. chemo which typically provides a benefit of between 5-9M, Oppenheimer adds.